Background Low maternal vitamin D has been associated with preterm birth (PTB). Human immunodeficiency virus (HIV)-infected pregnant women are at risk for PTB, but data on maternal vitamin D and PTB in this population are scarce. Methods In a cohort of Latin American HIV-infected pregnant women from the National Institute of Child Health and Human Development International Site Development Initiative protocol, we examined the association between maternal vitamin D status and PTB. Vitamin D status was defined as the following 25-hydroxyvitamin D levels: severe deficiency (< 10 ng/ mL), deficiency (10-20 ng/mL), insufficiency (21-29 ng/mL), and sufficiency (!30 ng/mL). PTB was defined as delivery at < 37 weeks' gestational age (GA). Logistic regression was used to assess the association between maternal vitamin D status and PTB. Results Of 715 HIV-infected pregnant women, 13 (1.8%) were severely vitamin D deficient, 224 (31.3%) were deficient, and 233 were (32.6%) insufficient. Overall, 23.2% (166/715) of pregnancies resulted in PTB (median GA of PTBs ¼ 36 weeks [interquartile range: 34-36]). In multivariate analysis, severe vitamin D deficiency was associated with PTB (odds ratio ¼ 4.7, 95% confidence interval: 1.3-16.8]). Conclusion Severe maternal vitamin D deficiency is associated with PTB in HIVinfected Latin American pregnant women. Further studies are warranted to determine if vitamin D supplementation in HIV-infected women may impact PTB.
Vitamin D status during pregnancy has been linked to maternal and pregnancy outcomes.
1 Preterm birth (PTB) is a pregnancy outcome associated with significant morbidity and mortality worldwide and is the leading cause of neonatal and childhood mortality in those under the age of 5 years. 2 Low maternal vitamin D status has been demonstrated in observational and clinical trials to be consistently associated with PTB. [3] [4] [5] [6] [7] [8] [9] [10] Human immunodeficiency virus (HIV)-infected pregnant women, particularly those receiving antiretroviral therapy (ART), are at an increased risk of PTB, 11, 12 but data regarding maternal vitamin D and PTB in women with HIV infection are scarce. 13 Because of this increased risk of PTB in HIV-infected women on ART, potential associations involving vitamin D pathways would be important to elucidate as vitamin D supplementation could have increased impact on a population already at an increased risk for PTB. The goal of this article was to investigate the association between maternal vitamin D status and PTB in a large prospective cohort of HIV-infected pregnant women in Latin America and the Caribbean.
Materials and Methods

Study Population
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) enrolled a prospective cohort of HIV-infected pregnant woman/infant dyads into the NICHD International Site Development Initiative (NISDI) Perinatal and Longitudinal Study in Latin American Countries (LILAC) protocols in Latin America and the Caribbean from 2002 to 2009. 14 A total of 17 sites across Argentina, the Bahamas, Brazil, Mexico, Peru, and Jamaica participated. The perinatal protocol enrolled HIV-infected pregnant women !8 weeks' gestational age (GA), while the LILAC protocol enrolled those !22 weeks' GA. Study visits were conducted antepartum (up to two visits), at delivery, and until 6 months (perinatal protocol) or 2 years (LILAC protocol) postpartum. Data including medical histories, physical examinations, and laboratory assessments (hematology, flow cytometry assays, HIV RNA levels, and biochemistries) were collected during maternal study visits. Plasma specimens were collected from maternal and pediatric participants and stored in a central repository at À80°C for potential future studies. An informed consent was obtained for all enrolled participants. The study was approved by the NICHD Institutional Review Board (IRB), the Westat Inc. IRB (Rockville, MD), and in-country ethics committees and national review boards (where appropriate). We restricted our study population to HIV-infected pregnant women enrolled for the first time (subsequent pregnancies were not included) in the NISDI perinatal and/or LILAC protocols with available antepartum blood specimens collected between 12 and 34 weeks' GA. In addition, only women whose pregnancies resulted in HIV-uninfected singleton live births were included.
Primary Outcome
The primary outcome was PTB, defined as delivery occurring at < 37 weeks' GA. These included both spontaneous and nonspontaneous PTBs. Infant GA at delivery was measured using obstetrical estimation by last menstrual period with or without ultrasound confirmation or by newborn examination.
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Primary Exposure of Interest
Maternal plasma 25-hydroxyvitamin D (25OHD) levels were measured on repository blood specimens using the Abbott Architect chemiluminescent microparticle immunoassay on the ARCHITECT i2000SR analyzer (Abbott Laboratories, Abbott Park, IL), according to the manufacturer's instructions, at ARUP Laboratories (Salt Lake City, UT). 19 Methods and results of these 25OHD assays have been previously reported. 20 Maternal vitamin D status was defined as: severe deficiency (< 10 ng/mL), deficiency (10-20 ng/mL), insufficiency (21-29 ng/mL), and sufficiency (! 30 ng/mL).
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Measurements
Data regarding other potential confounders were collected including maternal age, sociodemographics, anthropometrics, previous PTB, preeclampsia/eclampsia, CD4 cell count, HIV RNA level, substance use during pregnancy, and combination antiretroviral therapy (ART) use during pregnancy. Maternal body mass index (BMI) adjusted for GA at the time of enrollment was calculated. 22 CD4 cell count and HIV RNA levels were measured at the time of enrollment, and ART use during pregnancy was defined as the regimen lasting ! 28 days. Infant variables such as very low birth weight (VLBW) was defined as birth weight < 1,500 g, low birth weight (LBW) as birth weight ranging from 1,500 to 2,499 g, and small for gestational age (SGA) as per INTERGROWTH standards.
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Statistical Analysis
Characteristics at enrollment were compared between severely deficient, deficient, insufficient, and sufficient vitamin D status using Kruskal-Wallis, chi-square, or Fisher exact tests as appropriate. Variables at least marginally associated with PTB (p 0.10) were considered candidates for multivariable analysis. Logistic regression modeling was used to assess the association between maternal vitamin D status and PTB while adjusting for confounders. Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
Results
Among the 715 HIV-infected pregnant women included in this analysis, vitamin D status was severely deficient in 13 ( 
Discussion
In this large cohort of Latin American HIV-infected pregnant women, we found severe maternal vitamin D deficiency to be associated with PTB. Only one other study has been published to date assessing the association between maternal vitamin D and PTB in HIV-infected women. 13 This study of 884 HIV- The fact that we found evidence for increased PTB risk at the most severe levels of vitamin D deficiency and not at all levels of vitamin D deficiency or insufficiency is consistent with other studies.
3,7,9 Posthoc analyses of the two U.S. randomized clinical trials mentioned above showed that the positive association between maternal vitamin D levels and GA at birth was strongest at levels < 20 ng/mL and no association between maternal vitamin D levels of 20 to 39 ng/mL and PTB were found. 7 In addition, a large meta-analysis reported associations between low maternal vitamin D levels and PTB when the exposure of interest was dichotomized at 50 nmol/L (20 ng/mL) but not at 75 nmol/L (30 ng/mL). 9 This demonstrates that there may be a clinically significant and detectable effect of maternal vitamin D status only at the most severe level of deficiency. Of note, when we combined severely deficient and deficient vitamin D HIV-infected women into the same exposure group, we did not see an effect on PTB (data not shown). The mechanisms by which vitamin D may play a role in PTB amongst HIV-infected women remain unclear. The etiology of PTB is likely multifactorial but the emphasis has been placed on the role of inflammatory processes. help mitigate PTB by regulating inflammation. Of note, there was a significantly higher proportion of women receiving nonnucleoside reverse transcriptase inhibitors (NNRTIs) among women with severe vitamin D deficiency, and though ART type was not associated with PTB in our analysis, a potential link between NNRTI use, low maternal vitamin D status, and PTB could be explored. Our study was limited by the small number of women who had severe vitamin D deficiency and our inability to distinguish between spontaneous and nonspontaneous PTB. As a result, we may have overestimated the effect of severe maternal vitamin D deficiency on spontaneous PTB. In addition, we could not assess for vitamin D supplementation which may have occurred during the pregnancy. Finally, the range of GA at which antenatal vitamin D was assessed spanned all three trimesters with the majority occurring after 22 weeks' GA, making it difficult to pinpoint a particular time at which maternal vitamin D status is most strongly associated with PTB. However, vitamin D measurements taken closer to delivery have been shown to correlate more strongly with PTB. 8 In addition, our results were similar even in analyses stratified by GA at the time of vitamin D testing.
PTB results in both significant mortality and morbidity as well as an economic burden, particularly for resource-constrained settings. 30 These effects may be even more pronounced in HIV-exposed infants given their increased risk for poor growth 31, 32 and infections. 33 Severe maternal vitamin D deficiency appears to be associated with PTB in HIV-infected Latin American pregnant women. As vitamin D is a safe and inexpensive supplement, future studies are warranted to understand mechanisms by which vitamin D may affect PTB, including the ones regulated by vitamin D receptor and its polymorphisms affecting functionality at the 
